Myristoylated Alanine-Rich C-Kinase Substrate (MARCKS) is a critical acidic membrane-associated protein that regulates actin cytoskeletal dynamics, cell motility, and vesicular trafficking. As a primary substrate for Protein Kinase C (PKC), MARCKS acts as a molecular switch: when unphosphorylated, it binds actin filaments and sequester phosphatidylinositol 4,5-bisphosphate (PIP2) at the plasma membrane; upon PKC phosphorylation, it translocates to the cytosol, releasing PIP2 and remodeling the cytoskeleton. This pathway makes MARCKS a pivotal target in inflammatory diseases (such as ARDS and COPD) and oncology, where it drives cancer cell metastasis, invasion, and resistance to targeted therapies.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for MARCKS drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MARCKS Recombinant Protein (Full-length / Effector Domain) High purity (>95%), Endotoxin controlled. Sequence Verified. |
View MARCKS Products |
| Gene Delivery | MARCKS Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and overexpression. |
View MARCKS Products |
| Benchmark Ab | Anti-MARCKS Recombinant Antibody High-affinity positive control for Western Blot, IHC, and FACS. |
View MARCKS Products |
| Validator | MARCKS siRNA Set For target knockdown verification and specificity profiling. |
View MARCKS Products |
| Related Target A | PRKCA (PKC-alpha) Primary upstream kinase responsible for MARCKS phosphorylation and translocation. |
View PRKCA Products |
| Related Target B | EGFR MARCKS interacts with EGFR to promote signaling and mediate resistance to EGFR TKIs. |
View EGFR Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Phosphorylation-state specific assaying | Recombinant MARCKS proteins available in wild-type and phosphorylation-mimic mutant forms. |
| PIP2 binding and displacement screening | High-purity Effector Domain (ED) peptides and proteins verified for membrane association. |
| Lack of functional controls | Validated benchmark antibodies and custom siRNA knockdown pools included. |
| Off-target toxicity profiling | Subfamily panel screening reagents (e.g., MARCKSL1) available to ensure compound specificity. |
Live MARCKS R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of MARCKS is gaining momentum, moving beyond academic validation into clinical translation. Emerging strategies focus on disrupting the MARCKS-PIP2 interaction or preventing PKC-mediated phosphorylation to arrest cancer metastasis and hypersecretion in inflammatory airway diseases. While peptide-based inhibitors have pioneered this space, current research is actively exploring small molecule inhibitors and RNA interference (RNAi) modalities to overcome delivery barriers and improve intracellular targeting efficiency.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Peptide Inhibitors (e.g., BIO-11006) | BioMarck Pharmaceuticals | ARDS, COPD, Non-Small Cell Lung Cancer (NSCLC) | F-actin bundling and PIP2 displacement assays (Requires high-purity MARCKS Effector Domain) |
| siRNA / RNAi | Academic Institutions, Biotech Startups | Glioblastoma, Triple-Negative Breast Cancer (TNBC) | In vitro target knockdown validation (Requires sequence-verified siRNA and Lentiviral vectors) |
| Small Molecule Inhibitors | Preclinical Discovery Programs | Metastatic Cancers, Inflammatory Disorders | PKC phosphorylation assays (Requires wild-type MARCKS protein as a functional kinase substrate) |